iTeos Therapeutics, Inc. lost $3.32 per diluted share in fiscal year 2024. This represents a decrease of 5.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2024 through Q2 FY2025, the same line adds up to a loss of $4.69 per diluted share. The table below carries 6 fiscal years, from 2019 to 2024, and the quarters iTeos Therapeutics, Inc. has filed alongside them.
FY2024 annual
EPS (Diluted)-$3.32
YoY-5.4%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2025, ended Jun 30, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
ITOS EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was iTeos Therapeutics, Inc.'s diluted earnings per share in fiscal year 2024?
iTeos Therapeutics, Inc. lost $3.32 per diluted share in fiscal year 2024.
How fast is iTeos Therapeutics, Inc.'s diluted earnings per share growing?
iTeos Therapeutics, Inc. (ITOS) diluted earnings per share fell by 5.4% year over year, from -$3.15 to -$3.32 in fiscal year 2024.
What is iTeos Therapeutics, Inc.'s diluted earnings per share over the last twelve months?
iTeos Therapeutics, Inc. (ITOS) reported a loss of $4.69 per diluted share over the trailing 12 months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.
What was iTeos Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
iTeos Therapeutics, Inc. (ITOS) reported -$1.81 in diluted earnings per share in Q2 2025. This represents a decrease of 905.6% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what iTeos Therapeutics, Inc. (ITOS) reported on that line in every period on record.
